Development and validation of a reversed-phase HPLC method for the determination of ezetimibe in pharmaceutical dosage forms
- 15 September 2005
- journal article
- Published by Elsevier BV in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 39 (3-4), 517-522
- https://doi.org/10.1016/j.jpba.2005.04.026
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Ezetimibe: first in a new class of cholesterol absorption inhibitorsInternational Congress Series, 2004
- Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary HypercholesterolemiaCirculation, 2003
- Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial.European Heart Journal, 2003
- Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemiaThe American Journal of Cardiology, 2003
- Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemiaJournal of the American College of Cardiology, 2002
- Ezetimibe: efficacy and safety in clinical trialsEuropean Heart Journal Supplements, 2002
- Disposition of the selective cholesterol absorption inhibitor ezetimibe in healthy male subjects.Drug Metabolism and Disposition, 2002
- A population pharmacokinetic model that describes multiple peaks due to enterohepatic recirculation of ezetimibeClinical Therapeutics, 2001
- Internal standard high-performance liquid chromatography method for the determination of obidoxime in urine of organophosphate-poisoned patientsJournal of Chromatography B: Biomedical Sciences and Applications, 2001
- Optimization of A Reverse Phase Ion-Pair Chromatographic Separation for Drugs of Forensic Interest Part I - Variables Effecting Capacity FactorsJournal of Liquid Chromatography, 1981